These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 9199754)

  • 1. Allospecific CD4+, Th1/Th2 and CD8+, Tc1/Tc2 populations in murine GVL: type I cells generate GVL and type II cells abrogate GVL.
    Fowler DH; Breglio J; Nagel G; Hirose C; Gress RE
    Biol Blood Marrow Transplant; 1996 Oct; 2(3):118-25. PubMed ID: 9199754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
    Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE
    J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy.
    Jung U; Foley JE; Erdmann AA; Toda Y; Borenstein T; Mariotti J; Fowler DH
    Biol Blood Marrow Transplant; 2006 Sep; 12(9):905-18. PubMed ID: 16920556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
    Fowler DH; Gress RE
    Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.
    Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Vallera DA
    J Immunol; 1998 Jun; 160(11):5355-65. PubMed ID: 9605135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-stimulated/Tc2 cells abrogate murine marrow graft rejection.
    Erdmann AA; Jung U; Foley JE; Toda Y; Fowler DH
    Biol Blood Marrow Transplant; 2004 Sep; 10(9):604-13. PubMed ID: 15319772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease.
    Krenger W; Snyder KM; Byon JC; Falzarano G; Ferrara JL
    J Immunol; 1995 Jul; 155(2):585-93. PubMed ID: 7608537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
    Johnson BD; Becker EE; Truitt RL
    Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type 2 immune deviation has differential effects on alloreactive CD4+ and CD8+ T cells.
    Matesic D; Valujskikh A; Pearlman E; Higgins AW; Gilliam AC; Heeger PS
    J Immunol; 1998 Nov; 161(10):5236-44. PubMed ID: 9820495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
    Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
    Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia.
    Weiss L; Reich S; Slavin S
    Cytokines Cell Mol Ther; 1999 Sep; 5(3):153-8. PubMed ID: 10641573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo persistence of CD8 polarized T cell subsets producing type 1 or type 2 cytokines.
    Cerwenka A; Carter LL; Reome JB; Swain SL; Dutton RW
    J Immunol; 1998 Jul; 161(1):97-105. PubMed ID: 9647212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow.
    Truitt RL; Atasoylu AA
    Bone Marrow Transplant; 1991 Jul; 8(1):51-8. PubMed ID: 1833016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells in rheumatoid arthritis by flow cytometry.
    Berner B; Akça D; Jung T; Muller GA; Reuss-Borst MA
    J Rheumatol; 2000 May; 27(5):1128-35. PubMed ID: 10813277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graft-versus-myeloid leukemia responses following syngeneic and allogeneic bone marrow transplantation.
    Korngold R; Leighton C; Manser T
    Transplantation; 1994 Aug; 58(3):278-87. PubMed ID: 7914387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD8Tc1 and Tc2 cells secrete distinct cytokine patterns in vitro and in vivo but induce similar inflammatory reactions.
    Li L; Sad S; Kägi D; Mosmann TR
    J Immunol; 1997 May; 158(9):4152-61. PubMed ID: 9126975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells.
    Blazar BR; Taylor PA; Boyer MW; Panoskaltsis-Mortari A; Allison JP; Vallera DA
    J Immunol; 1997 Oct; 159(7):3460-73. PubMed ID: 9317145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity.
    Sykes M; Abraham VS; Harty MW; Pearson DA
    J Immunol; 1993 Jan; 150(1):197-205. PubMed ID: 8093257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Profiles of type 1 and type 2 T cells in chronic idiopathic thrombocytopenic purpura].
    Wang TT; Zhao H; Ren H; Guo JH; Xu MQ; Yang RC; Han ZC
    Zhonghua Yi Xue Za Zhi; 2006 Mar; 86(10):669-73. PubMed ID: 16681922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Th1 and Th2 CD4+ T cells and Tc1 and Tc2 CD8+ T cells of patients with Wegener's granulomatosis.
    Ohta N; Fukase S; Fuse T; Aoyagi M
    J Laryngol Otol; 2002 Aug; 116(8):605-9. PubMed ID: 12389688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.